Zilebesiran, a Small Interfering RNA agent as a potential novel antihypertensive treatment with cardiorenal protective effects: An overview of recent clinical trials

Hypertension is the primary risk factor for kidney and cardiovascular disease. Effective control of hypertension is important as reduction of blood pressure may effectively mitigate cardiovascular risks. The prevalence of uncontrolled hypertension persists, despite the widespread availability of antihypertensive medications. Poor adherence to medications is attributed to inadequate blood pressure control with current treatments. Zilebesiran, an investigational RNA interference therapeutic agent, targets hepatic angiotensinogen synthesis to provide sustained blood pressure reduction. It provides long-lasting pharmacological effects, requiring only twice a year or quarterly subcutaneous injection. Therefore, it is feasible to tackle the inadequate patient compliance with this drug. This review discusses its potential clinical impact, efficacy, and safety profile based on recent studies.